Zevra Therapeutics, Inc.
ZVRA Nasdaq
SEC CIK 1434647
Follow Zevra Therapeutics
Weekly email: filings, results
Revenue, last quarter
$37.8M
+44.9% vs same quarter last year
Net income
$19.2M
+3630.9% vs same quarter last year
EPS, diluted
$0.26
+2700% vs same quarter last year
Operating cash flow
$10M
+113.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $106.5M | $83.2M |
| FY24 | $23.6M | −$105.5M |
| FY23 | $27.5M | −$46M |
| FY22 | $10.2M | −$26.8M |
| FY21 | $28.7M | −$8.6M |
| FY20 | $13.3M | −$12.8M |
| FY19 | $12.8M | −$24.5M |
| FY18 | $0 | −$56.5M |
| FY17 | - | −$43.4M |
| FY16 | - | −$16.5M |
| FY15 | $0 | −$54.7M |
| FY14 | $0 | −$24.5M |
| FY13 | $0 | −$5.2M |
| FY12 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | −59.1% | 78.2% |
| FY24 | - | −368.5% | −446.9% |
| FY23 | 89.3% | −180.6% | −167.7% |
| FY22 | 97.8% | −418.9% | −263.5% |
| FY21 | 92.8% | 27% | −29.9% |
| FY20 | - | −42.2% | −96% |
| FY19 | 22.1% | −158.4% | −191% |
| FY18 | - | - | - |
| FY17 | - | - | - |
| FY16 | - | - | - |
| FY15 | - | - | - |
| FY14 | - | - | - |
| FY13 | - | - | - |
| FY12 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$2.4M |
| FY24 | −$69.7M |
| FY23 | −$33.8M |
| FY22 | −$18.8M |
| FY21 | $10.3M |
| FY20 | −$2M |
| FY19 | −$23.8M |
| FY18 | −$54.2M |
| FY17 | −$33.3M |
| FY16 | −$30.4M |
| FY15 | −$20.4M |
| FY14 | −$14.7M |
| FY13 | −$4.4M |
| FY12 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | $0 |
| FY23 | $3.4M |
| FY22 | $4.7M |
| FY21 | $2.8M |
| FY20 | $0 |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
- Zevra Therapeutics
- Healthcare median
Show the numbers
| Year | Zevra Therapeutics | Healthcare median |
|---|---|---|
| FY25 | 78.2% | −30.6% |
| FY24 | −446.9% | −47% |
| FY23 | −167.7% | −58% |
| FY22 | −263.5% | −80.4% |
| FY21 | −29.9% | −71.8% |
| FY20 | −96% | −62.2% |
| FY19 | −191% | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |